リコンビナント
expressed in baculovirus infected Sf9 cells
形状
liquid
濃度
5 mg/mL
色
off-white
UniProtアクセッション番号
輸送温度
dry ice
保管温度
−70°C
遺伝子情報
rat ... Abcb1b(24646)
詳細
Membrane Preparations for ATPase Assays are suitable for drug-efflux transporter interaction studies based on ATPase activity determination, and could be used for differentiation between transporter substrates and inhibitors.
アプリケーション
The ATPase assay is an in vitro membrane assay designed to indicate the nature of the interaction between the compound and the transporter. By measuring ATPase activity, both activation and inhibition of transporters can be investigated using membranes from baculovirus-infected insect cells or mammalian cell membranes containing high levels of human or rodent wild-type transporters. ABC transporters mediate the transport of substrates against a concentration gradient using energy derived from ATP hydrolysis, which is proportional to the transporter activity and could easily be detected with a colorimetric method.
To assess activation, ABC transporter-rich membranes are incubated with various (typically in 8) concentrations of the test article and the effect on basal ATPase activity is measured. Compounds that stimulate ATPase are generally considered substrates for the transporter. To assess inhibition, a test article′ ability to modify the activity of a given ABC transporter stimulated with its prototypical substrates is examined. The activation and inhibition tests are complementary assays.
Stimulation detected in the activation assay indicate that the compound is a transported substrate of the transporter, while interactions detected in the inhibition test indicate interaction of the test compounds with the transporter, but do not give information on the nature (substrate or inhibitor) of the interaction. In some cases inhibitors or slowly transported compounds may inhibit the baseline transporter ATPase activity as well.
Slowly transported substrates often do not stimulate the ATPase activity in a detectable extent; however the existing interaction can be identified in the inhibition assay.
To assess activation, ABC transporter-rich membranes are incubated with various (typically in 8) concentrations of the test article and the effect on basal ATPase activity is measured. Compounds that stimulate ATPase are generally considered substrates for the transporter. To assess inhibition, a test article′ ability to modify the activity of a given ABC transporter stimulated with its prototypical substrates is examined. The activation and inhibition tests are complementary assays.
Stimulation detected in the activation assay indicate that the compound is a transported substrate of the transporter, while interactions detected in the inhibition test indicate interaction of the test compounds with the transporter, but do not give information on the nature (substrate or inhibitor) of the interaction. In some cases inhibitors or slowly transported compounds may inhibit the baseline transporter ATPase activity as well.
Slowly transported substrates often do not stimulate the ATPase activity in a detectable extent; however the existing interaction can be identified in the inhibition assay.
物理的形状
Supplied as frozen membrane vesicles, containing 5 mg/ml membrane protein, labeled with volume, catalog number (transporter) and date of production.
法的情報
SOLVO Biotechnology, Inc.より提供。
関連製品
製品番号
詳細
価格
保管分類コード
12 - Non Combustible Liquids
WGK
WGK 1
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
SBAT07-1EA:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Siegfried Drescher et al.
British journal of clinical pharmacology, 53(5), 526-534 (2002-05-08)
The C3435T polymorphism in the human MDR1 gene is associated with lower intestinal P-glycoprotein expression, reduced protein function in peripheral blood cells and higher plasma concentrations of the P-glycoprotein substrate digoxin. Using fexofenadine, a known P-glycoprotein substrate, the hypothesis was
Drug-drug interactions of new active substances: mibefradil example.
M Siepmann et al.
European journal of clinical pharmacology, 56(3), 273-273 (2000-08-22)
MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese.
C G L Lee et al.
Journal of medical genetics, 41(5), e60-e60 (2004-05-04)
Zsuzsanna Rajnai et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(11), 2000-2006 (2010-08-12)
Seliciclib, a cyclin-dependent kinase inhibitor, is a promising candidate to treat a variety of cancers. Pharmacokinetic studies have shown high oral bioavailability but limited brain exposure to the drug. This study shows that seliciclib is a high-affinity substrate of ATP-binding
R B Wang et al.
Journal of clinical pharmacy and therapeutics, 28(3), 203-228 (2003-06-11)
A large number of structurally and functionally diverse compounds act as substrates or modulators of p-glycoprotein (p-gp). Some of them possess multiple drug resistance (MDR)-reversing activity, but only a small number of them have entered clinical study. In order to
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）